Stock News & Analysis

The AI server-maker is growing quickly, but will it last?

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

The retail coffee chain has focused aggressively on expanding its physical footprint.

Alvarez expanded her direct stake to 6 million shares at $17.98 per share, signaling confidence in the $37.2 billion financial institution's outlook.

It looked like a great fit... until it wasn't.

IREN stock has surged in recent years as the company pivots to AI cloud services.

One trades at a steep valuation premium despite deeper losses, while the other boasts a stronger balance sheet but faces government contract concentration.

The cloud platform operator struck a deal valued at up to $20 billion with an AI leader.

Nvidia is not known as a quantum computing company, but it's developing plenty of products to ensure that it's relevant in that nascent technology.

Rady's $1.1 million purchase brings his total beneficial stake to 24% of the REIT, signaling confidence in the premium property portfolio.

On Sept. 25, 2026, the productivity giant unveiled new AI capabilities designed to widen adoption and support premium monetization across its suite.

One entertainment giant is setting records across its biggest businesses at the same time. The other just guided below expectations and watched its stock drop sharply.

Comcast holds a revenue lead, but Disney's steady growth is narrowing the gap — a shift that could reshape the competitive dynamics between these media giants.

Banking giants are sending warning signals, suggesting that long-term investors should look at resilient businesses built to last.

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

The drugmaker badly needs more clinical wins.

On Sept. 25, 2026, analysts weighed in, with BNP Paribas cutting its price target to $268, keeping investor focus on near-term earnings expectations.

One company has sticky government contracts, improving margins, and a growing backlog. The other has working quantum hardware and a CHIPS Act funding letter, but revenue that remains tiny relative to its ambitions.

On Sept. 25, 2026, the analyst firm slashed its price target to $30 from $47, citing weak wholesale momentum and China sales challenges.

Machado acquired 62,048 shares at $17.98 each, expanding her direct stake by 36% to roughly 235,000 shares. The purchase occurred while the Brazilian bank's one-year return stood at 5%.